Butterfly Network, Inc. (BFLY): Results of Operations and Financial Condition
Butterfly Network, Inc. (BFLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bfly-20260730xexx991.htm EX-99.1 Document Exhibit 99.1 Butterfly Network Reports Second Quarter 2026 Financial Results Delivered Record Revenue and Adjusted EBITDA Loss Above Guidance • Raised full year Revenue and Improved Adjusted EBITDA Guidance • Delivered quarterly
How this was made
The 30-second read
Why it matters
The filing provides fresh, decision-relevant numbers: Q2 performance (revenue, gross margin, adjusted EBITDA loss) and explicit guidance ranges for FY 2026 and Q3 2026, plus operational milestones that can affect near-term demand and procurement eligibility.
Market read
Traders can reprice BFLY based on raised FY 2026 revenue and improved adjusted EBITDA loss guidance, plus concrete progress on government and international expansion.
What to watch
Key execution risks remain around FedRAMP certification in Q3 2026, Home & Community Care commercialization timing (revenue expected in Q4), and international probe sales volatility.
Background
This is an SEC Form 8-K (Item 2.02) with Butterfly Network’s Q2 2026 results and updated FY and Q3 guidance.
Ticker impact
Butterfly Network reported Q2 revenue of $32.6M (+39% YoY), raised FY 2026 revenue to $119M-$123M, and improved adjusted EBITDA loss guidance.
Likely positive near-term bias as guidance upgrades and higher gross margin support earnings expectations, with follow-through risk around FedRAMP timing and commercialization milestones.
The filing is a primary earnings/guidance disclosure with multiple quantified upgrades (revenue and adjusted EBITDA) plus concrete operational catalysts (FedRAMP provisional authorization, Brazil authorization, first commercial implementation timing).
Market effects
Supports sentiment for ultrasound hardware and AI-enabled point-of-care platforms, especially companies positioning toward enterprise software and government procurement.
Brazil regulatory authorization may improve perceived growth optionality in international ultrasound demand.
FedRAMP progress and embedded-partner expansion reinforce US government and partner ecosystem narratives that can influence broader medtech software adoption sentiment.
Counterpoint
Despite guidance raises, the company still reports net loss and adjusted EBITDA loss, so upside may be limited if operating expense growth outpaces revenue conversion.
Key entities
- issuerButterfly Network, Inc.
Reports Q2 2026 financial results and raises FY 2026 revenue and adjusted EBITDA loss guidance; highlights FedRAMP progress and Brazil regulatory authorization.
- regulatory_programFedRAMP
US government cloud security authorization pathway; company received provisional authorization and targets certification in Q3 2026.
- partnerVCOM
Medical education partner referenced for a long-term strategic partnership to support physician training transitions.
